international
-
Despite Long COVID’s ongoing impact, research in Colombia is limited
One of the few Long COVID research studies in Colombia is testing cognitive rehabilitation therapy. This approach recently failed in a U.S. clinical trial.
-
“Medically neglected” and “structurally erased”: International network appeals for ME advocate Nevra Elis
This fall, an international group of people known as Team Nevra has led an ongoing campaign to fundraise and help find care for Nevra Elis, an advocate living with severe myalgic encephalomyelitis (ME).
-
Research updates, December 9
A new study in the International Journal of Infectious Diseases examines how COVID-19 impacts the immune system.
-
“Not Recovered” protest for Long COVID, ME, and related diseases takes over The Hague
Demonstrations for post-acute infection syndromes including Long COVID, Lyme, and myalgic encephalomyelitis (ME) took place on November 30 in The Hague, Netherlands as a part of the #HetPAISProtest led by the group #NietHersteld (Not Recovered).
-
International Long COVID conference spotlights biomarker and mechanism research
The event, now in its third year, also revealed updates about clinical trials and healthcare for the disease.
-
Research updates, November 4
The German government is cutting millions of euros in Long COVID funding, according to the German business newspaper Handelsblatt.
-
Germany’s “Reha” clinics aren’t set up for Long COVID. And patients are reporting harm.
The country’s pension insurance system pushes people to go through rehabilitation (“Reha”) clinics before they can access disability supports.
-
The crisis is “exasperating”: Long COVID compounds economic hardship in Argentina
Argentina is facing an invisible Long COVID crisis, marked by a lack of clinics, minimal media attention, no disability insurance to help people with the disease cope with their inability to work, and only a couple of Long COVID studies — all amid a 48% cut to the national health budget under President Javier Milei.
-
Berlin Cures’ failed Long COVID clinical trial yields lessons on study design
After advertising a potential Long COVID “cure” in its novel drug, called BC 007 (rovunaptabin), the German start-up Berlin Cures abruptly concluded its phase II clinical trial with a brief press release in November 2024 announcing the study was unsuccessful. The Sick Times spoke with study participants and outside experts and found that, while some…
-
Experts call new Canadian Long COVID guidelines “contradictory” and “deeply concerning”
Guidelines recommend exercise and therapy as treatments, following attempted influence from Paul Garner.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance